2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Apoptosis, Pathogenesis, Genomics, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

4986 Dual HDAC and EZH2 inhibition coordinately remodels malignant B cells and the immune microenvironment in germinal center-derived B-cell lymphoma

Ted Piorczynski, PhD, Manuel Pazos, BS, MS2, Seda S. Tolu, MD3, Swanand Rakhade4, Chang Liu5, Aleksandar Z. Obradovic6, Jennifer Effie Amengual, MD7
1 Columbia University Irving Medical Center, New York, New York, United States
2 Columbia University Irving Medical Center, New York, New York, United States
3 Columbia University Irving Medical Center, New York, New York, United States
4 Columbia University Irving Medical Center, New York, New York, United States
5 Columbia University Irving Medical Center, New York, New York, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 Columbia University Irving Medical Center, New York, New York, United States
Background: Epigenetic dysregulation is a hallmark of germinal center-derived B-cell (GCB) lymphomas, contributing to impaired antigen presentation, reduced immune recognition, and disease progression. Combined histone deacetylase (HDAC) and EZH2 inhibition with belinostat (BEL) and tazemetostat (TAZ), respectively, reverses these epigenetic alterations. We hypothesize that dual HDAC and EZH2 inhibition epigenetically reprograms malignant B cells and coordinately modulates immune cells to enhance antigen presentation, immune-cell communication, and anti-lymphoma immunity, thereby promoting a more immunogenic tumor microenvironment.

Building on our previous demonstration that combined BEL+TAZ treatment restores antigen presentation, we sought to define the epigenetic mechanisms underlying these effects and evaluate their translational relevance.

Results: BEL+TAZ enhances B:T-cell interactions, visualized by live cell imaging of BEL+TAZ-treated SU-DHL-4 cells co-cultured with GFP-expressing F-actin T cells (n=3), indicating enhanced tumor-immune engagement. Consistent with this, primary follicular lymphoma spheroids pretreated with BEL+TAZ for six days exhibited enhanced autologous T cell-mediated lymphoma killing by both confocal microscopy and flow cytometry (n=3).

To define the epigenetic basis of this enhanced immunogenicity, OCI-Ly7 and SU-DHL-4 cells were analyzed by bulk RNA- and ATAC-seq following BEL+TAZ treatment (n=4). Dual BEL+TAZ broadly induced genes involved in antigen processing and presentation. Integrated RNA-seq, ATAC-seq, and H3K27me3 CUT&RUN analyses in SU-DHL-4 cells demonstrated coordinated chromatin remodeling and identified CD80, CIITA, ERAP1, HLA-DPB1, CD74, HLA-DRA, and ERAP2 as epigenetically regulated mediators of antigen presentation. Transcription factor enrichment and HOMER motif analyses further identified the RFX family as candidate regulators of this transcriptional program. Together, these findings identify coordinated epigenetic remodeling of antigen presentation pathways as a mechanistic basis for enhanced tumor-immune communication following dual HDAC and EZH2 inhibition.

To determine whether these epigenetic changes translated into enhanced anti-tumor immunity in vivo, female BALB/c mice bearing A20 GCB lymphoma tumors were treated with vehicle, BEL (80 mg/kg IP, once daily, 4 days/week), TAZ (200 mg/kg SC, once daily, 7 days/week), or BEL+TAZ (n=7–9/group). After 12 days, BEL+TAZ produced the greatest reduction in tumor volume (199.0 mm³) compared with BEL alone (211.4 mm³), TAZ alone (335.5 mm³), and vehicle controls (547.4 mm³). Correlative flow cytometry demonstrated increased tumor MHC-I expression and systemic T-cell activation, including expansion of activated and memory CD8+ T cells and increased CD25, CD69, CD44, and CD40L expression. Spatial transcriptomic tumor profiling further identified malignant B-cell populations with increased expression of MHC-I genes (H2-K1, H2-D1), MHC-II genes (H2-Dma, H2-Dmb2), B2m, and Cd74, supporting coordinated activation of antigen presentation pathways and anti-tumor immunity in vivo.

To determine whether these immune-modulatory effects translated clinically, paired peripheral blood samples from lymphoma patients enrolled in a BEL+TAZ clinical trial (NCT05627245) were analyzed by single-cell RNA sequencing before and after treatment (n=3). BEL+TAZ induced antigen processing and presentation pathways in both CD4+ and CD8+ T cells through gene ontology over-representation analyses. CD8+ T cells exhibited increased expression of GZMB, GZMH, and GZMM, consistent with enhanced cytotoxic activation, while peripheral B cells demonstrated increased expression of HLA-B, HLA-DQB1, HLA-DRA, and HLA-DRB1 following treatment. Ligand-receptor analyses further revealed enhanced immune communication between B cells and multiple immune cell populations, including CD4+ and CD8+ T cells, NK cells, and myeloid cells, supporting coordinated remodeling of tumor-immune communication following BEL+TAZ treatment.

Conclusions: Collectively, these findings demonstrate that combined HDAC and EZH2 inhibition coordinately reprograms malignant B cells and the immune microenvironment to enhance antigen presentation, immune communication, and anti-lymphoma immunity. By integrating mechanistic studies with complementary murine and patient analyses, these data support dual epigenetic therapy as a strategy to convert immune “cold” GCB lymphomas into a more immunogenic state.
Ted Piorczynski, PhD: No relevant conflicts of interest to declare.